Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:255505 |
| Acceso en línea: | https://ddd.uab.cat/record/255505 https://dx.doi.org/urn:doi:10.3390/ijms22094344 |
| Access Level: | acceso abierto |
| Palabra clave: | Psoriasis Pustular psoriasis Psoriatic arthritis Imsidolimab Spesolimab IL-36 IL-36R Pathogenesis |
| Sumario: | Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results. |
|---|